Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Dopamine D3 receptor antagonists may provide clues about receptor function

Nov. 25, 1998

Tasmar sales suspended in Canada

Nov. 24, 1998

Synapton NDA is nonapprovable, FDA says

Nov. 24, 1998

Substituted heteroaromatic 5-ht1f agonists in development at Lilly as antimigraine agents

Nov. 24, 1998

Novel CRF1-specific ligands claimed by Neurogen

Nov. 24, 1998

Pyridazine and phthalazine derivatives from SmithKline Beecham for CNS, neurological disorders

Nov. 24, 1998

Dual 5-HT reuptake inhibitor/5-HT1A antagonist discussed at neuroscience meeting

Nov. 24, 1998

Sch-50971: a novel histamine H3 agonist with antimigraine and sedative effects in preclinical models

Nov. 23, 1998

MK-0869 effective and well tolerated in patients with major depressive disorder

Nov. 23, 1998

Cytogen and Berlex finalize supply agreement with DuPont for Quadramet

Nov. 23, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...